Influenza vaccine information for health professionals

On this page:

Back to:

Immunization is the most effective strategy to reduce the impact of influenza in our community, as it can prevent or attenuate influenza illness, and reduce mortality, hospitalization, and complications, such as pneumonia. Ottawa Public Health will support your efforts to increase vaccine coverage in your facility by providing information and resources, and by having public health staff available for consultation.

The annual National Advisory Committee on Immunization (NACI) statement for 2016-2017 is posted on the Public Health Agency of Canada web site. NACI (2015) concludes that “egg allergic individuals may be vaccinated against influenza using TIV, without prior influenza vaccine skin test and with the full dose, irrespective of a past severe reaction to egg. 

What's new this year?

For children six months to 17 years, a quadrivalent injection is available that protects against four different flu virus strains: Fluzone Quadrivalent® and FluLaval Tetra® (subject to availability). This injection contains an additional B strain: B/Phuket/3073/2013-like virus along with A/California/7/2009(H1N1) pdm09-like virus, an A/Hong Kong/4801/2014 (H3N2)-like virus, B/Brisbane/60/2008-like virus strain. 


For children two years to 17 years, FluMist Quadrivalent® (a nasal spray influenza vaccine), is also available. It also provides protection against A/California/7/2009(H1N1) pdm09-like virus, A/Hong Kong/4801/2014 (H3N2)-like virus, B/Brisbane/60/2008-like virus, and B/Phuket/3073/2013-like virus. FluMist Quadrivalent® is a live attenuated influenza vaccine (LAIV) administered through the intranasal route and is recommended by the Canadian National Advisory Committee on Immunization (NACI) as an available quadrivalent option for children.

[ Top ]

Publicly Funded Influenza Vaccines 2016/2017





FluLaval Tetra® / Fluzone Quadrivalent®

Flumist® Quadrivalent

Influenza Vaccine Formulation

Trivalent inactivated vaccine (TIV)

Trivalent inactivated vaccine (TIV)

Trivalent inactivated vaccine (adjuvanted) (TIV-adjuvanted)

Quadrivalent inactivated vaccine (QIV)

Quadrivalent live attenuated vaccine (Q-LAIV)

Dosage/ Route of Administration

0.5mL / IM Injection

0.5mL / IM  Injection

0.5mL / IM


0.5mL / IM


0.2mL (0.1mL in each nostril) Nasal Spray

(see "Vaccines for Specific Age Groups" below)

6 months and older

18 years and older

65 years and older who reside in long-term care homes

6 months through 17 years

2 through 17 years

Potential Allergens

Agriflu: Egg protein^
Neomycin Thimerosal

Egg protein^

Egg protein^
Chicken protein

Egg protein^
Chicken protein

Egg protein^

Egg protein^

Egg protein^

 ^ Egg allergy is not a contraindication to receiving inactivated influenza vaccines or live attenuated influenza vaccine (see National Advisory Committee on Immunization Influenza Statement).

* Nominal supply of thimerosal free, single-dose prefilled syringe of Fluzone Quadrivalent vaccine is available for children aged 6 months to 17 years who have known thimerosal allergies.

Top ]

Which vaccine to choose:

Age Group

Recommended Vaccine

Alternative Vaccine

6 through 23 months


TIV (if requested or if QIV is not available)

2 through 17 years


TIV (if requested or if QIV or Q-LAIV is not available)

18 years and older



65 years and older who reside in long-term care homes


TIV (if requested or if TIV-adjuvanted is not available)

Top ]

Vaccine ordering and pick up

Vaccine Distribution Room hours are Monday to Friday, 8 am to 4 pm. NOTE: November 11 is a statutory holiday and the Vaccine Distribution Room will be closed.

  1. Use the Seasonal Influenza Vaccine Order Form from Ottawa Public Health, not the MOHLTC form
  2. Place your order in doses. Orders will be filled in the order they are received, with priority to high-risk groups. Please allow 7-10 business days for your order to be processed.
  3. Always reserve a small quantity of vaccine for persons age 65 and over, and persons under 65 with medical conditions that put them at high risk for influenza-related complications
  4. Your facility will be called when your order is ready. Arrange to pick up your order within 48 hours of notification at the Ottawa Public Health Vaccine Program, 100 Constellation Drive.
  5. Bring your own cooler and ice pack
  6. Vaccine that is not used by your facility cannot be redistributed. To reduce vaccine wastage, only order the quantity that you are sure to use. You can order more vaccine as needed.

Also available for downloading are:


Vaccine strains

During the 2015/2016 season, seven different influenza vaccine products will be distributed,

  • AGRIFLU® (Novartis), a trivalent vaccine that is supplied in 10-dose vials
  • FLUZONE®  (Sanofi Pasteur),a quadrivalent vaccine that is supplied in 10-dose vials
  • FLUVIRAL® (GSK, Inc.), a trivalent vaccine that is supplied in 10-dose vials\
  • FLUAD® (Novartis), an adjuvanted vaccine that is supplied in pre-filled syringes
  • FluLaval Tetra® (GSK Inc), a quadrivalent vaccine that is supplied in 10 dose vial
  • Influvac® (BGP Pharma Inc), a trivalent vaccine that is supplied in pre-filled syringes
  • Flumist® (AstraZeneca Canada), a quadrivalent live attenuated vaccine that is administered intra nasally

Except for the Flumist®, they are all split-virus, inactivated vaccines. They all contain the following antigens:

  • A/California/7/2009(H1N1)
  • A/Hong Kong/4801/2014 (H3N2)-like virus
  • B/Brisbane/60/2008-like virus strain
  • B/Phuket/3073/2013-like virus (for the quadrivalent only)


Influenza vaccine contraindications and precaution

Consult the product monograph 


Report of adverse events following immunization (AEFI)

All adverse events following administration of an influenza vaccine must be reported to Ottawa Public Health within 24 hours by fax to 613-580-9660, attention to Kerry Kennedy using the AEFI form [PDF 200 KB]. If you have any questions related to the reporting of adverse events following immunization, please call 613-580-6744, ext. 23504.


Health care Agencies and workplaces excluding doctors providing influenza vaccine clinics

Immunization is the single most effective means to reduce the impact of influenza, as it can prevent or attenuate influenza illness, reduce complications such as pneumonia, hospitalizations, and mortality.

Ottawa Public Health seeks to support you in your efforts to increase vaccine coverage in your facility by offering information and resources, and by having public health staff available for consultation. For information on the 2016/2017 Seasonal UIIP, please email

Return unused vaccine to the Ottawa Public Health Vaccine Program once your clinics are finished for the season using Ottawa Public Health Vaccine Return Form.


More information

  • Ministry of Health and Long-Term Care (MOHLTC)
  • Ottawa Public Health Immunization contact information
    • Forms and resources
    • To order vaccine fax the Influenza vaccine order form to 613-580-2783
    • Questions regarding a vaccine order 613-580-6744, ext. 24225 or email
    • Vaccine-associated adverse events reporting form fax to 613-580-9660, questions 613-580-6744
    • Hospitals, long-term care, retirement homes call the outbreak reporting line 613-580-6744 ext 26325
    • Workplaces call Ottawa Public Health Information 613-580-6744, ext. 15414
  • Manufacturers’ telephone numbers:
    • Sanofi Pasteur (Vaxigrip® and Fluzone®) 1-888-621-1146,
    • Novartis (Fluad® and Agriflu®) 1-888-363-8883
    • GlaxoSmithKline, Inc. (Fluviral®) and fluLavalTetra® 1-800-387-7374
    • BGP Pharma Inc Influvac ® 1-800-699-9948
    • AstraZeneca Canada (Flumist®) 1-800-461-3787